ACAD Stock Analysis: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$22.09
0.47 (2.17%)
▲
5d:
+4.74%
30d:
+5.44%
90d:
+6.51%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.1/10
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ACAD shows positive signals but monitor for confirmation. Market pricing in 3.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ACAD shows positive signals but monitor for confirmation. Market pricing in 3.1% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.47
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$26.99
18.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $22.09, which is considered extended relative to its 30-day fair value range of $20.99 to $21.76. The stock's valuation (Forward PE: 24.7) is in line with its historical norms (27.2). Remarkably, the market is currently pricing in an annual earnings decline of 3.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ACAD is in a downtrend. The price is approaching resistance at $22.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACAD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.65 (+43.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACAD is in a downtrend. The price is approaching resistance at $22.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACAD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.65 (+43.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$20.99 -
$21.76
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.3% below Wall St target ($31.65)
Trading Range Analysis
30-Day Trading Range
$20.99 -
$21.76
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$20.84
Resistance Level
$22.46
Current Trend
Downtrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.74
Wall Street Target
$31.65
(+43.3%)
Revenue Growth (YoY)
9.7%
Earnings Growth (YoY)
-81.8%
Profit Margin
34.3%
Valuation Discount vs History
-3.1% cheaper
PE vs Historical
24.7 vs 27.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.1%
(market-implied from PE analysis)
1-Year Target
$21.41
(-3%)
2-Year Target
$20.74
(-6%)
3-Year Target
$20.10
(-9%)
3-Yr Target (if PE normalizes)
(PE: 25→27)
$22.10
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.7, Growth: 124.8%)
$74.55
(+238%)
Base:
(SPY PE: 21.8, Growth: 124.8%)
$65.64
(+197%)
Bear:
(PE: 18.5, Growth: 124.8%)
$55.80
(+153%)
📈
Valuation based on Current Earnings
Trailing PE: 9.78 | Current EPS (TTM): $2.21
Bull Case
$11.89
(-46%)
Analyst growth -50.0%, PE expands to 10.8
Base Case
$10.81
(-51%)
Market implied -50.0%, PE stable at 9.8
Bear Case
$14.70
(-33%)
Severe decline -20.0%, PE contracts to 8.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.7 to 27.2
Stabilization Target:
$24.29
(+10.0%)
PE Expansion Potential:
+10.0%
Share & Embed Analysis
Last updated: June 23, 2026 8:22 AM ET
Data refreshes hourly during market hours. Next update: 9:22 AM
Data refreshes hourly during market hours. Next update: 9:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
James Kihara
SELL
1030 shares
2026-04-07
Mark C Schneyer
SELL
2709 shares
2026-04-07
Jennifer J Rhodes
SELL
6950 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 66 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 59 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 64 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
MNMD
Mind Medicine Inc |
STRONG BUY
11 analysts |
$29 | 62 BUY |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
